Insight

Giselle Sholler: Our research that led to the FDA-Oncologic Drugs Advisory Committee 70% approval for moving Difluoromethylornithine forward

Photo of Giselle Sholler from cbtn.org

Dec 10, 2023, 18:01

Giselle Sholler: Our research that led to the FDA-Oncologic Drugs Advisory Committee 70% approval for moving Difluoromethylornithine forward

Giselle Sholler, Division Chief Pediatric Hematology/Oncology/BMT at Penn State Health Children’s Hospital, shared on LinkedIn:

“Our research that led to the FDA-ODAC 70% approval for moving DFMO forward had been published in the Journal of Clinical Oncology!! I am so proud of our Beat Childhood Cancer Research Consortium at Penn State College of Medicine in collaboration with US WorldMeds for this article. We are hopeful and optimistic that this research will successfully navigate the drug through the approval process!”

For the article click here.
Source: Giselle Sholler/LinkedIn

article Beat Childhood Cancer Research Consortium cancer DFMO FDA Giselle Sholler OncoDaily Oncology Penn State College of Medicine Research US WorldMeds

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage